Vident Investment Advisory LLC Has $2.30 Million Position in MacroGenics Inc (MGNX)

Vident Investment Advisory LLC boosted its holdings in MacroGenics Inc (NASDAQ:MGNX) by 24.2% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 111,449 shares of the biopharmaceutical company’s stock after acquiring an additional 21,716 shares during the quarter. Vident Investment Advisory LLC owned 0.26% of MacroGenics worth $2,301,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in MGNX. State Board of Administration of Florida Retirement System increased its position in shares of MacroGenics by 16.0% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 20,497 shares of the biopharmaceutical company’s stock valued at $423,000 after purchasing an additional 2,830 shares during the last quarter. Stifel Financial Corp increased its position in shares of MacroGenics by 18.1% during the 1st quarter. Stifel Financial Corp now owns 19,766 shares of the biopharmaceutical company’s stock valued at $500,000 after purchasing an additional 3,033 shares during the last quarter. Rhumbline Advisers increased its position in shares of MacroGenics by 11.4% during the 2nd quarter. Rhumbline Advisers now owns 37,119 shares of the biopharmaceutical company’s stock valued at $767,000 after purchasing an additional 3,804 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of MacroGenics during the 1st quarter valued at about $119,000. Finally, Swiss National Bank increased its position in shares of MacroGenics by 8.6% during the 1st quarter. Swiss National Bank now owns 64,700 shares of the biopharmaceutical company’s stock valued at $1,628,000 after purchasing an additional 5,100 shares during the last quarter. Institutional investors and hedge funds own 92.84% of the company’s stock.

MGNX has been the topic of several recent research reports. ValuEngine upgraded MacroGenics from a “hold” rating to a “buy” rating in a research report on Thursday, September 13th. Cowen reiterated a “buy” rating on shares of MacroGenics in a research report on Wednesday, August 8th. Zacks Investment Research lowered MacroGenics from a “buy” rating to a “hold” rating in a research report on Saturday, August 11th. BidaskClub upgraded MacroGenics from a “hold” rating to a “buy” rating in a research report on Friday, June 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $34.00 price objective on shares of MacroGenics in a research report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $30.50.

NASDAQ MGNX opened at $20.19 on Tuesday. MacroGenics Inc has a fifty-two week low of $16.12 and a fifty-two week high of $32.74. The company has a market capitalization of $905.57 million, a price-to-earnings ratio of -37.39 and a beta of 2.41.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.17. MacroGenics had a negative return on equity of 13.01% and a negative net margin of 19.20%. The business had revenue of $18.83 million during the quarter, compared to analysts’ expectations of $4.41 million. As a group, sell-side analysts forecast that MacroGenics Inc will post -4.77 earnings per share for the current year.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.

Featured Article: What is the NASDAQ?

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply